Nanotheranostics With the Combination of Improved Targeting, Therapeutic Effects, and Molecular Imaging

Shin-Lei Peng,Chih-Ho Lai,Pei-Yi Chu,Jer-Tsong Hsieh,Yen-Chun Tseng,Shao-Chieh Chiu,Yu-Hsin Lin

DOI: https://doi.org/10.3389/fbioe.2020.570490

IF: 5.7

2020-09-15

Frontiers in Bioengineering and Biotechnology

Abstract:There is an increasing interest in the design of targeted carrier systems with combined therapeutic and diagnostic modalities. Therapeutic modalities targeting tumors with single ligand-based targeting nanocarriers are insufficient for proficient delivery and for targeting two different surface receptors that are overexpressed in cancer cells. Here, we evaluated an activated nanoparticle delivery system comprising fucoidan/hyaluronic acid to improve therapeutic efficacy. The system comprised polyethylene glycol-gelatin-encapsulated epigallocatechin gallate (EGCG), poly (D,L-lactide-co-glycolide; PLGA), and stable iron oxide nanoparticles (IOs). The latter enables targeting of prostate cancers in their molecular images. We demonstrate the transfer of nanoparticles and their entry into prostate cancer cells through ligand-specific recognition. This system may prove the benefits of drug delivery that enhances the inhibition of cell growth through apoptosis induction. Moreover, the improved targeting of nanotheranostics significantly suppressed orthotopic prostate tumor growth and more accurately targeted tumors compared with systemic combination therapy. In the presence of nanoparticles with iron oxides, the hypointensity of the prostate tumor was visualized on a T2-weignted magnetic resonance image. The diagnostic ability of this system was demonstrated by accumulating fluorescent nanoparticles in the prostate tumor from the <i>in vivo</i> imaging system, computed tomography. It is suggested that theranostic nanoparticles combined with a molecular imaging system can be a promising cancer therapy in the future.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a nano - diagnosis - and - treatment system that can simultaneously improve targeting, treatment efficacy and molecular imaging capabilities. Specifically, the researchers designed a composite nanoparticle system containing polyethylene glycol - gelatin (PEG - gelatin), epigallocatechin gallate (EGCG), poly(D, L - lactic - co - glycolic acid; PLGA) and stable iron oxide nanoparticles (IOs). This system uses fucoidan (FU) and hyaluronic acid (HA) to achieve efficient targeting of prostate cancer cells, and enhances the anti - cancer effect through the loading of EGCG. In addition, the presence of iron oxide nanoparticles enables this system to be used for molecular imaging of tumors in magnetic resonance imaging (MRI), thus providing a new nano - diagnosis - and - treatment platform integrating diagnosis and treatment.

The key issues mentioned in the paper include:
- **Improving targeting**: Traditional single - ligand - targeted nanocarriers have deficiencies in delivery efficiency and multi - receptor targeting. In this study, by combining FU and HA, it aims to target multiple over - expressed receptors on the tumor cell surface simultaneously to improve targeting efficiency.
- **Enhancing treatment efficacy**: By loading EGCG, use its inhibitory effect on prostate cancer cells, especially to inhibit cell growth by inducing apoptosis.
- **Achieving molecular imaging**: By integrating iron oxide nanoparticles, this system not only has a treatment function, but also can generate high - resolution and high - contrast images in MRI for accurate tumor localization and monitoring.

In conclusion, this study aims to develop a multifunctional nano - diagnosis - and - treatment platform to overcome the limitations in existing cancer treatment methods, especially in targeted delivery, treatment efficacy and diagnostic imaging.